TCGA-A1-A0SE-01A-11R-A084-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 44
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.520
- ESTROGEN_RESPONSE_EARLY+0.480
- ESTROGEN_RESPONSE_LATE+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- APICAL_SURFACE+0.360
- APICAL_JUNCTION+0.300
- WNT_BETA_CATENIN_SIGNALING+0.270
- MITOTIC_SPINDLE+0.260
- PROTEIN_SECRETION+0.240
- TGF_BETA_SIGNALING+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.350
- COMPLEMENT-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- MTORC1_SIGNALING-0.280
- IL2_STAT5_SIGNALING-0.210
- MYC_TARGETS_V2-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313124 | — | B | 0.831 |
| 2 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.819 |
| 3 | TCGA-AN-A0XO-01A-11R-A109-07 | — | C | 0.814 |
| 4 | SRR1313121 | — | B | 0.804 |
| 5 | 20050073.LumB | — | B | 0.797 |
| 6 | SRR25617938 | — | B | 0.795 |
| 7 | SRR8518326 | — | E | 0.787 |
| 8 | TCGA-A8-A086-01A-11R-A00Z-07 | — | B | 0.786 |
| 9 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.780 |
| 10 | TCGA-S3-AA14-01A-11R-A41B-07 | — | A | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.520 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.480 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.410 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |